Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma.

Authors: Qin, Yan-Ru  Qiao, Jun-Jing  Chan, Tim Hon Man  Zhu, Ying-Hui  Li, Fang-Fang  Liu, Haibo  Fei, Jing  Li, Yan  Guan, Xin-Yuan  Chen, Leilei 
Citation: Qin YR, etal., Cancer Res. 2014 Feb 1;74(3):840-51. doi: 10.1158/0008-5472.CAN-13-2545. Epub 2013 Dec 3.
Pubmed: (View Article at PubMed) PMID:24302582
DOI: Full-text: DOI:10.1158/0008-5472.CAN-13-2545

Esophageal squamous cell carcinoma (ESCC), the major histologic form of esophageal cancer, is a heterogeneous tumor displaying a complex variety of genetic and epigenetic changes. Aberrant RNA editing of adenosine-to-inosine (A-to-I), as it is catalyzed by adenosine deaminases acting on RNA (ADAR), represents a common posttranscriptional modification in certain human diseases. In this study, we investigated the status and role of ADARs and altered A-to-I RNA editing in ESCC tumorigenesis. Among the three ADAR enzymes expressed in human cells, only ADAR1 was overexpressed in primary ESCC tumors. ADAR1 overexpression was due to gene amplification. Patients with ESCC with tumoral overexpression of ADAR1 displayed a poor prognosis. In vitro and in vivo functional assays established that ADAR1 functions as an oncogene during ESCC progression. Differential expression of ADAR1 resulted in altered gene-specific editing activities, as reflected by hyperediting of FLNB and AZIN1 messages in primary ESCC. Notably, the edited form of AZIN1 conferred a gain-of-function phenotype associated with aggressive tumor behavior. Our findings reveal that altered gene-specific A-to-I editing events mediated by ADAR1 drive the development of ESCC, with potential implications in diagnosis, prognosis, and treatment of this disease.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
RGD Object Information
RGD ID: 14700707
Created: 2019-08-13
Species: All species
Last Modified: 2019-08-13
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.